Latest news with #StéphaneBoyer
CTV News
2 days ago
- Business
- CTV News
Laval and police brotherhood sign ‘bold' new collective agreement
The City of Laval and the Police Brotherhood signed a new collective agreement for the Laval Police Service on Friday—a deal Mayor Stéphane Boyer described as 'fairly bold, fairly innovative compared to other police forces.' The agreement, in principle, was ratified by 78 per cent of the police brotherhood's members. It includes the transfer of certain administrative duties to civilian staff, freeing up 20,000 additional investigative hours for police officers—at a lower cost to the city. The new contract also introduces the deployment of cadets across Laval to manage traffic, representing another salary-saving measure for the municipality. In terms of compensation, the agreement includes salary increases totalling 22.2 per cent over five years. This figure combines base wage hikes with 'urban security premiums' tied to the unique challenges officers face in large urban centres. The city also aimed to boost police presence on the streets to strengthen residents' sense of safety. In an interview, Mayor Boyer said he was particularly proud of the deal. 'What we were looking for was greater efficiency and more officers on the streets. This agreement allows us to achieve that. And in my view, it's quite a bold and innovative deal compared to other police forces—recovering thousands of hours of investigation and street presence. We're really pleased with the outcome, and I think it's going to be a win-win, both for the officers and for the public,' said Boyer. Sylvain Tardif, president of the Laval Police Brotherhood, also welcomed the new agreement, saying it 'recognizes the dedication and professionalism officers bring to their work every day in keeping Laval residents safe.' 'The new contract offers working conditions that reflect the growing responsibilities of our officers, who work in a complex environment and are facing an evolving and increasingly sophisticated criminal landscape,' Tardif added. Pierre Brochet, director of the Laval Police Service, also noted that the new agreement will allow police to 'fight crime more effectively, while ensuring a stronger presence in the community.' The collective agreement will be in effect from Jan. 1, 2024, to Dec. 31, 2028. This report by The Canadian Press was first published in French on June 6, 2025. By Lia Lévesque, The Canadian Press
Cision Canada
05-05-2025
- Health
- Cision Canada
KEDRION CELEBRATES PLASMINOGEN AWARENESS DAY BY HIGHLIGHTING QUEBEC-MADE INNOVATION FOR A RARE DISEASE Français
Laval facility at the heart of global efforts to treat ultra-rare genetic disorder PLGD-1. LAVAL, QC, May 5, 2025 /CNW/ - Kedrion Biopharma, a global biopharmaceutical company, is proud to mark Plasminogen Awareness Day with a special event at its Laval facility, celebrating the development and ongoing production of RYPLAZIM ® (plasminogen, human-tvmh), the world's first and only approved treatment for plasminogen deficiency type 1 (PLGD-1), an ultra-rare genetic disorder. PLGD-1 is a rare genetic disorder caused by a deficiency in plasminogen, a protein essential for breaking down fibrin, a substance involved in blood clotting and tissue healing. Without sufficient plasminogen, fibrin can accumulate abnormally on all mucous membranes throughout the body, leading to painful and potentially serious complications, most commonly affecting the inner lining of the eyelidsbut potentially affecting all organs with mucous membranes. Left untreated, PLGD-1 has the potential to cause vision loss, breathing difficulties, and chronic inflammation, significantly impairing quality of life and, in severe cases, becoming life-threatening. Originally developed by Quebec-based biopharmaceutical company Prometic, which was acquired by Kedrion, RYPLAZIM is now manufactured at Kedrion's Laval facility and represents a medical and scientific breakthrough for patients affected by this debilitating condition, which impacts approximately 1.6 individuals per million worldwide. The treatment is currently approved for use in the United States. Kedrion is actively working with Canadian health authorities to seek broader recognition and eventual registration of the therapy in Canada. The scientific breakthrough behind this therapy is credited to a team of Quebec scientists led by Pierre Laurin, a visionary in the biotechnology sector, who pioneered the development of a novel plasma protein purification system. This innovation made it possible to isolate rare plasma proteins—such as plasminogen—that are typically lost in standard plasma fractionation processes. Personally committed to the cause of rare diseases, he dedicated himself to creating tangible solutions for patients who are too often left without effective treatment options. While RYPLAZIM is not yet approved for general use in Canada, patients in Quebec may access the therapy on a case-by-case basis through Health Canada's Special Access Program. In the province, distribution is coordinated through Héma-Québec. This exception-based access remains essential for the small number of individuals living with PLGD-1, offering a critical treatment option where no alternative is available. The Laval event is part of a global series of activities taking place simultaneously in Fort Lee (United States) and Bolognana (Italy), underscoring Kedrion's international commitment to addressing rare diseases. The Mayor of Laval, Stéphane Boyer, attended the event alongside patient advocates, medical experts, and members of the Kedrion team. " At Kedrion, we believe that every patient deserves access to life-changing therapies, no matter how rare their condition may be. The work accomplished here in Laval is a powerful example of Quebec's scientific leadership and the global impact of our innovations," said Sophie Larabée, Site Leader at Kedrion Biopharma. Kedrion continues to collaborate with patient foundations and regulatory authorities to raise awareness, improve access, and ensure that innovative therapies like RYPLAZIM reach those who need them, here in Canada and around the world. Among these partners is the Plasminogen Deficiency Foundation, established in 2020–2021, which plays a vital role in supporting individuals living with PLGD globally, regardless of geography. About Kedrion Biopharma Kedrion Biopharma is a global biopharmaceutical company specializing in the collection and fractionation of human plasma to produce and distribute therapies for rare and serious diseases. With a strong presence in North America, Europe, and emerging markets, Kedrion is committed to improving the lives of patients worldwide through the development and delivery of plasma-derived treatments. Its Laval facility plays a critical role in the company's innovation ecosystem, having led the development of RYPLAZIM—the first and only approved treatment for plasminogen deficiency type 1 (PLGD-1).
